# RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

> **NCT03699956** · PHASE3 · TERMINATED · sponsor: **EpicentRx, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **COMBINATION_PRODUCT:** RRx-001 + eLOOP Device
- **DRUG:** Cisplatin/carboplatin plus etoposide

## Key facts

- **NCT ID:** NCT03699956
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-24
- **Primary completion:** 2022-08-11
- **Final completion:** 2024-03-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** RRx-001 will be studied under a new global, phase 3 clinical trial
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699956, "RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03699956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*